Statins Reduce the Risk of Cirrhosis and Its Decompensation in Chronic Hepatitis B Patients: A Nationwide Cohort Study

American Journal of Gastroenterology

Volumn 111, Issue 7, 2016, Pages 976-985

  Huang, Yi Wen ^a,b,c   Lee, Chia Long ^a,b   Yang, Sien Sing ^a,d   Fu, Szu Chieh ^a   Chen, Yun Yi ^a,e   Wang, Ting Chuan ^a   Hu, Jui Ting ^a,d   Chen, Ding Shinn ^c,f,g  

^a CATHAY GENERAL HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^g GENOMICS RESEARCH CENTER   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACIPIMOX; ADEFOVIR DIPIVOXIL; ANTILIPEMIC AGENT; BEZAFIBRATE; CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; DIETHYLAMINOETHYLDEXTRAN; ENTECAVIR; ETOFIBRATE; EZETIMIBE; FENOFIBRATE; GEMFIBROZIL; HEPATITIS B SURFACE ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAMIVUDINE; NICERITROL; NICOFURANOSE; PROBUCOL; SIMFIBRATE; TELBIVUDINE;

ADULT; AGED; ARTICLE; ASCITES; CHRONIC HEPATITIS B; COHORT ANALYSIS; COMORBIDITY; DECOMPENSATED LIVER CIRRHOSIS; DIABETES MELLITUS; DOSE RESPONSE; DRUG USE; FEMALE; FOLLOW UP; HEPATIC COMA; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER PROTECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; OBESITY; POPULATION RESEARCH; PRIORITY JOURNAL; PROPENSITY SCORE; RISK REDUCTION; TAIWANESE; TREATMENT DURATION; VERY ELDERLY; COMPLICATION; DISEASE COURSE; DYSLIPIDEMIAS; HEPATITIS B, CHRONIC; INCIDENCE; INSURANCE; PATHOLOGY; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; PROTECTION; RISK FACTOR; STATISTICS AND NUMERICAL DATA; TAIWAN;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; COMORBIDITY; DISEASE PROGRESSION; DYSLIPIDEMIAS; FEMALE; HEPATITIS B, CHRONIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; INSURANCE CLAIM REVIEW; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROTECTIVE FACTORS; RISK FACTORS; TAIWAN;

EID: 84966587156     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2016.179     Document Type: Article

References (37)

1. Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis 2002; 2: 395-403.
2. Chen DS. From hepatitis to hepatoma: lessons from type B viral hepatitis. Science 1993; 262: 369-70.
3. Peng CY, Chien RN, Liaw YF. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J Hepatol 2012; 57: 442-50.
4. Perz JF, Armstrong GL, Farrington LA et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529-38.
5. Yang YH, Chen WC, Tsan YT et al. Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection. J Hepatol 2015; 63: 1111-7; pii: S0168-8278(15)00469-9.
6. Simon TG, King LY, Zheng H et al. Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C. J Hepatol 2015; 62: 18-23.
7. Abraldes JG, Albillos A, Bañares R et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 2009; 136: 1651-8.
8. Tsan YT, Lee CH, Ho WC et al. Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection. J Clin Oncol 2013; 31: 1514-21.
9. Tsan YT, Lee CH, Wang JD et al. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J Clin Oncol 2012; 30: 623-30.
10. Chiu HF, Ho SC, Chen CC et al. Statin use and the risk of liver cancer: a population-based case-control study. Am J Gastroenterol 2011; 106: 894-8.
11. Chen CI, Kuan CF, Fang YA et al. Cancer risk in HBV patients with statin and metformin use: a population-based cohort study. Medicine (Baltimore) 2015; 94: e462.
12. Hsiang JC, Wong GL, Tse YK et al. Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: a propensity-score landmark analysis. J Hepatol 2015; 63: 1190-7; pii: S0168- 8278(15)00472-9.
13. Rockey DC, Chung JJ. Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension. Gastroenterology 1998; 114: 344-51.
14. Shah V, Toruner M, Haddad F et al. Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat. Gastroenterology 1999; 117: 1222-8.
15. Abraldes JG, Rodriguez-Vilarrupla A, Graupera M et al. Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats. J Hepatol 2007; 46: 1040-6.
16. Zafra C, Abraldes JG, Turnes J et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology 2004; 126: 749-55.
17. Trebicka J, Hennenberg M, Laleman W et al. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology 2007; 46: 242-53.
18. Ramirez G, Briceno J, Rojas A. Statins and portal hypertension: a new pharmacological challenge. Curr Vasc Pharmacol 2012; 10: 767-72.
19. Abraldes JG, Tarantino I, Turnes J et al. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology 2003; 37: 902-8.
20. Stevens CE, Beasley RP, Tsui J et al. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 1975; 292: 771-4.
21. Ko YC, Li SC, Yen YY et al. Horizontal transmission of hepatitis B virus from siblings and intramuscular injection among preschool children in a familial cohort. Am J Epidemiol 1991; 133: 1015-23.
22. Hsu SC, Chang MH, Ni YH et al. Horizontal transmission of hepatitis B virus in children. J Pediatr Gastroenterol Nutr 1993; 16: 66-9.
23. Liu J, Yang HI, Lee MH et al. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology 2010; 139: 474-82.
24. Tseng TC, Liu CJ, Su TH et al. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology 2011; 141: 517-25.
25. Tseng TC, Liu CJ, Yang HC et al. Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load. Hepatology 2012; 55: 68-76.
26. Huang YW, Wang TC, Lin SC et al. Increased risk of cirrhosis and its decompensation in chronic hepatitis B patients with newly diagnosed diabetes: a nationwide cohort study. Clin Infect Dis 2013; 57: 1695-702.
27. Huang YW, Yang SS, Fu SC et al. Increased risk of cirrhosis and its decompensation in chronic hepatitis C patients with new onset diabetes: a nationwide cohort study. Hepatology 2014; 60: 807-14.
28. Fu SC, Huang YW, Wang TC et al. Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with new onset diabetes: a nationwide cohort study. Aliment Pharmacol Ther 2015; 41: 1200-9.
29. Huang YW, Wang TC, Yang SS et al. Increased risk of hepatocellular carcinoma in chronic hepatitis C patients with new onset diabetes: a nationwide cohort study. Aliment Pharmacol Ther 2015; 42: 902-11.
30. Fu SC, Huang YW. Editorial: diabetes and its association with hepatocellular carcinoma in chronic hepatitis B-authors' reply. Aliment Pharmacol Ther 2015; 42: 118-9.
31. WHO Collaborating Centre for Drug Statistics Methodology, Norwegian Institute of Public Health. Oslo, Norway: ATC/DDD Index 2012. Available at: http://www.whocc.no/atc-ddd-index/ (accessed 14 April 2014).
32. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45: 613-9.
33. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141-54.
34. Eberlein M, Heusinger-Ribeiro J, Goppelt-Struebe M. Rho-dependent inhibition of the induction of connective tissue growth factor (CTGF) by HMG CoA reductase inhibitors (statins). Br J Pharmacol 2001; 133: 1172-80.
35. Paradis V, Dargere D, Bonvoust F et al. Effects and regulation of connective tissue growth factor on hepatic stellate cells. Lab Invest 2002; 82: 767-74.
36. Marrone G, Russo L, Rosado E et al. The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by stations. J Hepatol 2013; 58: 98-103.
37. Yu ST, Chang HY, Lin MC et al. Agreement between self-reported and health insurance claims on utilization of health care: a population study. J Clin Epidemiol 2009; 62: 1316-22.